Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids

被引:21
作者
Henry, Brian L. [1 ,2 ]
Thakkar, Jay N. [1 ,2 ]
Martin, Erika J. [4 ]
Brophy, Donald F. [3 ]
Desai, Umesh R. [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA
[2] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA
[3] Virginia Commonwealth Univ, Dept Pharm, Richmond, VA 23219 USA
[4] Virginia Commonwealth Univ, Coagulat Special Studies Lab, Richmond, VA 23219 USA
关键词
anticoagulant agents; clotting times; dehydropolymers; hemostasis analysis system; thrombin inhibition; thromboelastography; PLATELET CONTRACTILE-FORCE; THROMBIN; HEPARIN; INHIBITION; ABILITY; CLOTS;
D O I
10.1097/MBC.0b013e328304e077
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Recently, we designed sulfated dehydropolymers (DHPs) of 4-hydroxycinnamic acids that displayed interesting anticoagulant properties. Structurally and mechanistically, sulfated DHPs are radically different from all the anticoagulants studied to date. To assess whether their unique mechanism and structure is worth exploiting for further rational design of homogeneous DHP-based molecules, we investigated their anticoagulant potential in human plasma and blood using a range of clotting assays. Sulfated DHPs prolong plasma clotting times, prothrombin and activated partial thromboplastin times at concentrations comparable to the clinically used low-molecular-weight heparin, enoxaparin. Fibrin formation studies on human plasma show that there is a structural dependence of anticoagulant action. Human whole blood studies using thromboelastography and hemostasis analysis system indicate that they are 17-140-fold less potent than enoxaparin. These results demonstrate that sulfated DHPs possess good in-vitro and ex-vivo activity, which will likely be improved through a rational design. Blood Coagul Fibrinolysis 20:27-34 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 27 条
[1]
[Anonymous], 2004, COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001100.PUB2
[2]
New insights into how blood clots: Implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy [J].
Bajaj, SP ;
Joist, JH .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1999, 25 (04) :407-418
[3]
Fondaparinux: an update on new study results [J].
Bauersachs, RM .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 :27-32
[4]
Buller HR, 2007, NEW ENGL J MED, V357, P1105
[5]
Buller HR, 2007, NEW ENGL J MED, V357, P1094
[6]
Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391
[7]
Carr Marcus E Jr, 2004, Clin Lab, V50, P529
[8]
Carr ME, 1996, THROMB HAEMOSTASIS, V75, P674
[9]
CARR ME, 1995, THROMB HAEMOSTASIS, V73, P499
[10]
Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT) [J].
Carr, ME ;
Martin, EJ ;
Kuhn, JG ;
Spiess, BD .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (09) :1977-1983